CPRX — Catalyst Pharmaceuticals, Inc. stock price, charts and financials
QT74Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 17.49 | EPS (ttm) | 1.80 | Insider Own | 13.31% | Shs Outstand | 122.42M | Perf Week | 0.00% |
| Market Cap | 3.85B | Forward P/E | 13.08 | EPS next Y | 2.41 | Insider Trans | 0.00% | Shs Float | 115.58M | Perf Month | 0.35% |
| Enterprise Value | 3.10B | PEG | 2.07 | EPS next Q | - | Inst Own | - | Short Float | 0.29% | Perf Quarter | 20.79% |
| Income | 221.66M | P/S | 6.46 | EPS this Y | 12.91% | Inst Trans | - | Short Ratio | 0.13 | Perf Half Y | 38.72% |
| Sales | 596.96M | P/B | 3.80 | EPS next Y | 23.21% | ROA | 19.29% | Short Interest | 340.26K | Perf YTD | 34.92% |
| Book/sh | - | P/C | 18.49 | EPS next 5Y | 8.73% | ROE | 23.65% | 52W High | 32.56 -3.29% | Perf Year | 49.74% |
| Cash/sh | - | P/FCF | 18.52 | EPS past 3/5Y | 30.84% 18.80% | ROIC | 19.67% | 52W Low | 19.05 65.30% | Perf 3Y | 144.87% |
| Dividend Est. | - | EV/EBITDA | 9.27 | Sales past 3/5Y | 40.14% 37.69% | Gross Margin | 82.32% | Volatility | 0.00% 0.09% | Perf 5Y | 472.55% |
| Dividend TTM | - | EV/Sales | 5.20 | EPS Y/Y TTM | 32.06% | Oper. Margin | 44.83% | ATR (14) | 0.05 | Perf 10Y | 3831.83% |
| Dividend Ex-Date | - | Quick Ratio | 6.84 | Sales Y/Y TTM | 21.34% | Profit Margin | 37.08% | RSI (14) | 70.17 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.10 | EPS Q/Q | -23.53% | SMA20 | 0.07% | Beta | 0.75 | Target Price | 31.75 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 5.67% | SMA50 | 0.44% | Rel Volume | 0.00 | Prev Close | 31.49 |
| Employees | 182 | LT Debt/Eq | 0.00 | Earnings | Aug 05 | SMA200 | 22.80% | Avg Volume | 2.49M | Price | 31.49 |
| IPO Date | Nov 08, 2006 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.47% -0.12% | Net Debt/EBITDA | -2.25 | Volume | 0 | Change | 0.00% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-28-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $35 → $32 |
| May-08-26 | Downgrade | Citigroup | Buy → Neutral | |
| May-07-26 | Downgrade | Stephens & Co. | Overweight → Equal Weight | $32 |
| Nov-07-25 | Reiterated | Oppenheimer | Outperform | $32 → $33 |
| Mar-03-25 | Reiterated | Robert W. Baird | $28 → $32 | |
| Feb-04-25 | Initiated | Baird | Outperform | $28 |
| Jan-10-25 | Reiterated | HC Wainwright & Co. | Buy | $24 → $35 |
| Dec-21-22 | Reiterated | HC Wainwright & Co. | Buy | $18 → $24 |
| Dec-21-22 | Reiterated | Truist Securities | Buy | $17 → $18 |
| Aug-24-22 | Downgrade | Roth Capital | Buy → Neutral | $16 |
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 597 | 589 | 492 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 105 | 87 | 69 | — | — | — | — | — | — | |
| Gross Profit | 492 | 502 | 423 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 195 | 194 | 178 | — | — | — | — | — | — | |
| Research and Development | 12 | 13 | 13 | — | — | — | — | — | — | |
| Other Operating Expense | 17 | 37 | 37 | — | — | — | — | — | — | |
| Operating Income | 267 | 258 | 195 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 29 | 26 | 21 | — | — | — | — | — | — | |
| Net Income Before Taxes | 296 | 284 | 216 | — | — | — | — | — | — | |
| Income Taxes | 74 | 69 | 52 | — | — | — | — | — | — | |
| Consolidated Net Income | 222 | 214 | 164 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 222 | 214 | 164 | — | — | — | — | — | — | |
| Net Income | 222 | 214 | 164 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.80 | 1.75 | 1.38 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.80 | 1.75 | 1.38 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.73 | 1.68 | 1.31 | — | — | — | — | — | — | |
| EBITDA | 334 | 321 | 254 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 18.20 | 13.89 | 15.93 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.44 | 4.83 | 5.01 | — | — | — | — | — | — | |
| Gross Margin | 82.41 | 85.23 | 85.98 | — | — | — | — | — | — | |
| Operating Margin | 44.72 | 43.80 | 39.63 | — | — | — | — | — | — | |
| Net Margin | 37.19 | 36.33 | 33.33 | — | — | — | — | — | — | |
| Shares Outstanding | 122 | 122 | 118 | — | — | — | — | — | — | |
| Market Capitalization | 3,842 | 2,847 | 2,463 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Andrews William T. | Chief Medical Officer | Jun 03 '26 | Option Exercise | 0.00 | 3,052 | 0 | 3,052 | Jun 05 |
| Andrews William T. | Chief Medical Officer | Jun 03 '25 | Option Exercise | 0.00 | 3,052 | 0 | 240,195 | Jun 05 |
| Russo Gregg | Chief HR Officer | Feb 17 '26 | Option Exercise | 0.00 | 687 | 0 | 687 | Feb 19 |
| Kalb Michael Wayne | Executive Vice President & CFO | Jan 05 '26 | Option Exercise | 0.00 | 7,139 | 0 | 15,745 | Jan 06 |
| Daly Richard J | President and CEO | Jan 05 '26 | Option Exercise | 0.00 | 42,105 | 0 | 281,843 | Jan 06 |
| Del Carmen Jeffrey | Chief Commercial Officer | Dec 29 '25 | Option Exercise | 0.00 | 8,667 | 0 | 18,176 | Dec 30 |
| Tierney David S | Director | Dec 29 '25 | Option Exercise | 0.00 | 1,334 | 0 | 383,314 | Dec 30 |
| Sundaram Preethi | Chief Strategy Officer | Dec 29 '25 | Option Exercise | 0.00 | 6,667 | 0 | 57,173 | Dec 30 |
| Miller Steve | Chief Op. & Scientific Officer | Dec 29 '25 | Option Exercise | 0.00 | 14,000 | 0 | 1,093,803 | Dec 30 |
| Harper Molly | Director | Dec 29 '25 | Option Exercise | 0.00 | 1,334 | 0 | 3,694 | Dec 30 |
| MCENANY PATRICK J | director, other: Chairman of Board of Directors | Dec 29 '25 | Option Exercise | 0.00 | 26,334 | 0 | 4,178,345 | Dec 30 |
| Daly Richard J | President and CEO | Dec 29 '25 | Option Exercise | 0.00 | 1,334 | 0 | 240,262 | Dec 30 |
| DENKHAUS DONALD A | Director | Dec 29 '25 | Option Exercise | 0.00 | 1,334 | 0 | 498,773 | Dec 30 |
| Elsbernd Brian | Chief Compliance/Legal Officer | Dec 29 '25 | Option Exercise | 0.00 | 6,667 | 0 | 245,124 | Dec 30 |
| Harper Molly | Director | Dec 12 '25 | Sale | 23.25 | 26,746 | 621,920 | 2,360 | Dec 16 |